Cargando…
Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease?
Inflammatory bowel diseases (IBDs) are immune-mediated, chronic relapsing diseases with a rising prevalence worldwide in both adult and pediatric populations. Treatment options for immune-mediated diseases, including IBDs, are traditional steroids, immunomodulators, and biologics, none of which are...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348973/ https://www.ncbi.nlm.nih.gov/pubmed/34361038 http://dx.doi.org/10.3390/ijms22158274 |
_version_ | 1783735471000518656 |
---|---|
author | Baradaran Ghavami, Shaghayegh Asadzadeh Aghdaei, Hamid Sorrentino, Dario Shahrokh, Shabnam Farmani, Maryam Ashrafian, Fatemeh Dore, Maria Pina Keshavarz Azizi Raftar, Shahrbanoo Mobin Khoramjoo, Seyed Zali, Mohammad Reza |
author_facet | Baradaran Ghavami, Shaghayegh Asadzadeh Aghdaei, Hamid Sorrentino, Dario Shahrokh, Shabnam Farmani, Maryam Ashrafian, Fatemeh Dore, Maria Pina Keshavarz Azizi Raftar, Shahrbanoo Mobin Khoramjoo, Seyed Zali, Mohammad Reza |
author_sort | Baradaran Ghavami, Shaghayegh |
collection | PubMed |
description | Inflammatory bowel diseases (IBDs) are immune-mediated, chronic relapsing diseases with a rising prevalence worldwide in both adult and pediatric populations. Treatment options for immune-mediated diseases, including IBDs, are traditional steroids, immunomodulators, and biologics, none of which are capable of inducing long-lasting remission in all patients. Dendritic cells (DCs) play a fundamental role in inducing tolerance and regulating T cells and their tolerogenic functions. Hence, modulation of intestinal mucosal immunity by DCs could provide a novel, additional tool for the treatment of IBD. Recent evidence indicates that probiotic bacteria might impact immunomodulation both in vitro and in vivo by regulating DCs’ maturation and producing tolerogenic DCs (tolDCs) which, in turn, might dampen inflammation. In this review, we will discuss this evidence and the mechanisms of action of probiotics and their metabolites in inducing tolDCs in IBDs and some conditions associated with them. |
format | Online Article Text |
id | pubmed-8348973 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83489732021-08-08 Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease? Baradaran Ghavami, Shaghayegh Asadzadeh Aghdaei, Hamid Sorrentino, Dario Shahrokh, Shabnam Farmani, Maryam Ashrafian, Fatemeh Dore, Maria Pina Keshavarz Azizi Raftar, Shahrbanoo Mobin Khoramjoo, Seyed Zali, Mohammad Reza Int J Mol Sci Review Inflammatory bowel diseases (IBDs) are immune-mediated, chronic relapsing diseases with a rising prevalence worldwide in both adult and pediatric populations. Treatment options for immune-mediated diseases, including IBDs, are traditional steroids, immunomodulators, and biologics, none of which are capable of inducing long-lasting remission in all patients. Dendritic cells (DCs) play a fundamental role in inducing tolerance and regulating T cells and their tolerogenic functions. Hence, modulation of intestinal mucosal immunity by DCs could provide a novel, additional tool for the treatment of IBD. Recent evidence indicates that probiotic bacteria might impact immunomodulation both in vitro and in vivo by regulating DCs’ maturation and producing tolerogenic DCs (tolDCs) which, in turn, might dampen inflammation. In this review, we will discuss this evidence and the mechanisms of action of probiotics and their metabolites in inducing tolDCs in IBDs and some conditions associated with them. MDPI 2021-07-31 /pmc/articles/PMC8348973/ /pubmed/34361038 http://dx.doi.org/10.3390/ijms22158274 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Baradaran Ghavami, Shaghayegh Asadzadeh Aghdaei, Hamid Sorrentino, Dario Shahrokh, Shabnam Farmani, Maryam Ashrafian, Fatemeh Dore, Maria Pina Keshavarz Azizi Raftar, Shahrbanoo Mobin Khoramjoo, Seyed Zali, Mohammad Reza Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease? |
title | Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease? |
title_full | Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease? |
title_fullStr | Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease? |
title_full_unstemmed | Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease? |
title_short | Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease? |
title_sort | probiotic-induced tolerogenic dendritic cells: a novel therapy for inflammatory bowel disease? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348973/ https://www.ncbi.nlm.nih.gov/pubmed/34361038 http://dx.doi.org/10.3390/ijms22158274 |
work_keys_str_mv | AT baradaranghavamishaghayegh probioticinducedtolerogenicdendriticcellsanoveltherapyforinflammatoryboweldisease AT asadzadehaghdaeihamid probioticinducedtolerogenicdendriticcellsanoveltherapyforinflammatoryboweldisease AT sorrentinodario probioticinducedtolerogenicdendriticcellsanoveltherapyforinflammatoryboweldisease AT shahrokhshabnam probioticinducedtolerogenicdendriticcellsanoveltherapyforinflammatoryboweldisease AT farmanimaryam probioticinducedtolerogenicdendriticcellsanoveltherapyforinflammatoryboweldisease AT ashrafianfatemeh probioticinducedtolerogenicdendriticcellsanoveltherapyforinflammatoryboweldisease AT doremariapina probioticinducedtolerogenicdendriticcellsanoveltherapyforinflammatoryboweldisease AT keshavarzaziziraftarshahrbanoo probioticinducedtolerogenicdendriticcellsanoveltherapyforinflammatoryboweldisease AT mobinkhoramjooseyed probioticinducedtolerogenicdendriticcellsanoveltherapyforinflammatoryboweldisease AT zalimohammadreza probioticinducedtolerogenicdendriticcellsanoveltherapyforinflammatoryboweldisease |